{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-273278","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.989019+00:00","generated_at":"2026-05-16T22:25:05.007961+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Wave Life Sciences Q3 net loss $53.9M; obesity drug WVE-007 shows 85% Activin E reduction","bullets":["WVE-007: dose-dependent Activin E reduction up to 85% in INLIGHT; sustained through 6 months at lowest dose; supports once/twice yearly dosing.","WVE-006 recapitulated MZ phenotype: AAT >20 µM during acute phase, wild-type M-AAT 64% of serum AAT, Z-AAT reduced 60% in RestorAATion-2.","Cash $196.2M at Sept 30; $72.1M post-quarter from ATM and GSK milestones extend runway into Q2 2027.","Net loss $53.9M vs $61.8M prior year; revenue $7.6M vs ($7.7M); R&D $45.9M, G&A $18.1M.","Milestones: INLIGHT body weight data Q4 2025; NDA for WVE-N531 in 2026; IND for WVE-003 Phase 2/3 H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-273278","json":"https://secwatch.observer/filing/0001193125-25-273278.json","markdown":"https://secwatch.observer/filing/0001193125-25-273278.md","text":"https://secwatch.observer/filing/0001193125-25-273278.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525273278/0001193125-25-273278-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312525273278/d44041d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:25:05.007961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}